Insights

Innovative Therapies Call for an Integrated Drug Safety and Compliance Model

In this article, Herbert Lee, PharmD, Senior Vice President, Medical Communications and Pharmacovigilance, makes the case for an integrated approach to ensuring the safe and effective use of medications by patients. From emerging therapies to innovative…

Articles

biosimilar care pathways
Care pathways—do you know where your biosimilars are used?

Biological therapies are often very expensive, putting pressure on healthcare budgets that are already restricted and potentially resulting in a decrease in patient access to treatment, in Europe biosimilar versions have been eagerly awaited in many…

biosimilar prioritization
Is your biosimilar product on the payer radar?

Biosimilars have been eagerly awaited in many European countries to realize cost savings from the biologics budget. Gaining insight on how European decision makers are currently prioritizing these biosimilars and how they expect this to shift…

‘Tis the season for pharma in China, as the government expedites uptake of new urgently needed drugs

PRICENTRIC BRIEF: Universal health insurance coverage for 1.3 billion people means China must increase uptake of “clinically urgently needed new drugs” already approved in the US, EU, and Japan Mostly oncology products are being imported, along…

“Who wants the biggest slice of the biosimilar pie?”: The Humira biosimilar wave in Europe

PRICENTRIC BRIEF: Biosimilar competition in Europe has brought about discounts to AbbVie’s blockbuster immunosuppressant drug Humira upwards of 80% during tendering Overall, biosimilar uptake has increased in Europe because biologic “copycats” are cheaper, but full faith…

no-image
How the Proposed Elimination of Medicare Rebates Would Impact Clinical Pathways

Government, Policy & Systems Changes Affecting Clinical Pathways This article is written by Dr. Richard Stefanacci, for Clinical Pathways Magazine. The Centers for Medicare & Medicaid Services (CMS) has published a range of new proposed and…

Medicare & Medicaid: A Rollback on Rebates

In January 2019, the Department of Health and Human Services (HHS) put forth a proposed rule to repeal the safe harbor status for Medicare and Medicaid drug rebates under the Anti-Kickback statute. This idea was first…

Product Master Data Management

This white paper shares  considerations, common pitfalls and key takeaways for manufacturers participating in Medicaid. Recent market and enforcement trends in healthcare further exemplify the transition from a volume to value-based marketplace, as well as the complexities to…

Precision Medicine Meets Precision Patient Support

In the value-driven healthcare environment, orphan drug manufacturers are becoming increasingly aware that improving adherence requires a new approach to patient understanding and support. Take for example the required lifestyle, nutritional or physical modifications often necessary…

Biosimilar Pricing in Europe

This report titled Biosimilar Pricing in Europe is published by Pricentric, by EVERSANA. It examines the pricing and pricing trends of biosimilar drugs in the US and EU5. It particularly looks at the pricing of Infliximab…

Wearables In Clinical Trials

Pharma Voice Magazine features Sandra Shpilberg from Seeker Health, an EVERSANA company, in their March 2019 issue. The topic is “Wearables in Clinical Trial”.  The article discusses how wearables are improving the clinical trial experience for patients…